by James Rudge, PhD, Technical Director, Neoteryx | 5 min read
An article published by Iris Xie, Yang Xu and Kevin Bateman et al in the April 2018 issue of the Journal of Pharmaceutical and Biomedical Analysis, reported on the importance …
Read Storyby Neoteryx | 4 min read
Blood sampling is an invaluable part of clinical research, but blood collection methods and blood storage chains are resource-intensive and sometimes wasteful. Most traditional blood collection methods require in-patient visits …
Read Storyby Neoteryx | 4 min read
As the COVID-19 crisis continues to wreak havoc on public health, international relations and the world economy, all eyes are on our research scientists in the hope they can develop …
Read Storyby Neoteryx | 1 min read
When Fasha Mahjoor launched Neoteryx, he planned to change the way dried capillary blood is collected, to become the most significant blood microsampling innovator in the modern marketplace. In that, …
Read Storyby Neoteryx | 2 min read
Therapeutic drug monitoring (TDM) immunosuppressants are a critical component of post-tissue and organ transplantation therapy. This is because ISP drugs have high intra- and inter-subject variability and a narrow therapeutic …
Read Storyby Neoteryx | 2 min read
When administering immunosuppressants, clinicians need to individualize a patient’s drug therapy. The goal is to attain an optimal balance between therapeutic efficacy and the probability of adverse effects. Patients present …
Read StoryLearn about insights, research, case studies, and tutorials on integrating remote specimen collection, microsampling, and more!
© Neoteryx 2021 | Privacy Policy | Sitemap
421 Amapola Ave
Torrance, CA 90501
This site is protected by reCAPTCHA and the Google Privacy
Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of biological fluids. They are CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada, Thailand, and Ukraine. In the United States, Mitra devices are for Research Use Only (RUO). In some countries, Mitra devices may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system in compliance with relevant rules and regulations. Mitra is a registered trademark of Neoteryx, LLC.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use. hemaPEN® is a registered trademark owned by Trajan Scientific Australia Pty Ltd.
Copyright © 2022 Neoteryx, LLC, Part of the Trajan Family. All rights reserved.